After testing positive for COVID, your medicine prescription will depend on the severity of your symptoms and any other health conditions you have.
Articles on Antivirals
Displaying 21 - 34 of 34 articles
Here’s who is eligible, the benefits and side effects to consider.
An infectious disease doctor discusses the use, benefits and availability of a drug to prevent severe COVID-19.
Earlier detection and treatment of COVID-19 by health care providers in pharmacies could help prevent surges in infection rates and severe illness.
Most people with COVID will recover at home without any treatment. But some people who are at risk of severe disease could benefit from new medicines to reduce the chance of the disease progressing.
Merck and Pfizer both have oral antiviral pills under review by the FDA. Such treatments could help turn the tide of the pandemic.
Medications to treat COVID-19 are in no way a substitute for the vaccine. But under the right circumstances, some show great promise for helping patients.
Researchers around the world are using new and existing technology to develop potential treatments for those with COVID-19. Here’s what’s in development in Australia.
This treatment would work by targeting the SARS-CoV-2 virus itself and stopping it in its tracks. The evidence we have so far is promising, but it’s still very early days.
This antibody protects patients from viruses, even while on immunosuppressant drugs.
Lorna Jane landed in hot water this week after promoting a new line of its activewear as “antiviral”. They’ve pulled back, but are still claiming the line is antibacterial – and that’s worrying too.
Kinases are cellular control switches. When they malfunction, they can cause cancer. The coronavirus hijacks these kinases to replicate, and cancer drugs that target them could fight COVID-19.
Scanning through billions of chemicals to find a few potential drugs for treating COVID-19 requires computers that harness together thousands of processors.
Getting rid of this scourge is nothing to be sneezed at.
Top contributors
-
Assistant Professor of Infectious Diseases, University of Virginia
-
Director, Australian Living Evidence Collaboration; Professor (Research), School of Population Health and Preventive Medicine, Monash University
-
Associate Professor, Epidemiology, Deakin University
-
Professor of Biostatistics and Epidemiology, Adelaide University
-
Monash University
-
Director, Intensive Care Unit, Alfred Health; Professor, Epidemiology and Preventative Medicine, Monash University
-
Post doctoral researcher and medical epidemiologist, The Peter Doherty Institute for Infection and Immunity
-
Associate Professor and Research Leader in Virology and Infectious Disease, Griffith University
-
Distinguished Professor, Professor of Immunology, RMIT University
-
Adjunct Associate Professor of Epidemiology, University of California, Los Angeles
-
Research Fellow, Institute for Glycomics, Griffith University
-
Associate Professor of Comparative Effectiveness and Outcomes Research, University of Connecticut
-
Distinguished Professor of Pharmacy Practice, University of Connecticut
-
Griffith University
-
Senior Lecturer, University of Technology Sydney